/R E P E A T -- MediPharm Labs Sets Date to Report Second Quarter 2024 Financial Results/
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), a pharmaceutical company specialized in precision-based cannabinoids, has announced the release date for its second quarter 2024 financial results. The results for the period ended June 30, 2024, will be released before markets open on Wednesday, August 14, 2024. The company's executive management team will host a conference call and audio webcast on the same day at 8:30 a.m. Eastern time to discuss the financial results. Participants can join via a North America Toll-Free number or an International Toll number. An audio webcast will also be available, with a replay accessible on the company's website for those unable to attend the live event.
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), una società farmaceutica specializzata in cannabinoidi di precisione, ha annunciato la data di rilascio dei risultati finanziari del secondo trimestre 2024. I risultati per il periodo chiuso il 30 giugno 2024, saranno pubblicati prima dell'apertura dei mercati mercoledì 14 agosto 2024. Il team di gestione esecutivo dell'azienda ospiterà una call conferenza e un audio webcast lo stesso giorno alle 8:30 ora orientale per discutere i risultati finanziari. I partecipanti possono unirsi tramite un numero verde per il Nord America o un numero a pagamento internazionale. Sarà disponibile anche un audio webcast, con una registrazione accessibile sul sito web dell'azienda per coloro che non possono partecipare all'evento dal vivo.
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), una empresa farmacéutica especializada en cannabinoides de precisión, ha anunciado la fecha de publicación de sus resultados financieros del segundo trimestre de 2024. Los resultados para el período que finalizó el 30 de junio de 2024 se publicarán antes de la apertura del mercado el miércoles 14 de agosto de 2024. El equipo de gestión ejecutiva de la compañía llevará a cabo una llamada de conferencia y una transmisión de audio en vivo el mismo día a las 8:30 a.m. hora del Este para discutir los resultados financieros. Los participantes pueden unirse a través de un número gratuito de América del Norte o un número internacional de paga. También estará disponible una transmisión de audio, con una grabación accesible en el sitio web de la empresa para aquellos que no puedan asistir al evento en vivo.
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), 정확성 기반의 카나비노이드 전문 제약 회사가 2024년 2분기 재무 결과 발표 날짜를 발표했습니다. 2024년 6월 30일자로 종료된 기간의 결과는 2024년 8월 14일 수요일 시장 개장 전에 발표됩니다. 회사의 경영진 팀은 같은 날 동부 표준시 기준 오전 8시 30분에 재무 결과에 대해 논의하는 컨퍼런스 콜 및 오디오 웹캐스트를 주최할 것입니다. 참가자는 북미의 무료 전화번호 또는 국제 유료 전화번호를 통해 참여할 수 있습니다. 라이브 행사에 참석할 수 없는 분들을 위해 회사 웹사이트에서 재생 가능한 오디오 웹캐스트도 제공될 예정입니다.
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), une entreprise pharmaceutique spécialisée dans les cannabinoïdes basés sur la précision, a annoncé la date de publication de ses résultats financiers pour le deuxième trimestre de 2024. Les résultats pour la période se terminant le 30 juin 2024 seront publiés avant l'ouverture des marchés le mercredi 14 août 2024. L'équipe de direction de l'entreprise organisera une conférence téléphonique et un webinaire audio le même jour à 8h30, heure de l'Est, pour discuter des résultats financiers. Les participants peuvent se joindre par un numéro sans frais pour l'Amérique du Nord ou un numéro à tarif international. Un webinaire audio sera également disponible, avec une rediffusion accessible sur le site Web de l'entreprise pour ceux qui ne peuvent pas assister à l'événement en direct.
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), ein pharmazeutisches Unternehmen, das sich auf präzisionsbasierte Cannabinoide spezialisiert hat, hat das Datum für die Veröffentlichung der finanziellen Ergebnisse für das zweite Quartal 2024 bekannt gegeben. Die Ergebnisse für den Zeitraum bis zum 30. Juni 2024 werden vor Markteröffnung am Mittwoch, den 14. August 2024 veröffentlicht. Das Management-Team des Unternehmens wird am selben Tag um 8:30 Uhr Eastern Time eine Konferenzschaltung und Audio-Webcast veranstalten, um die finanziellen Ergebnisse zu besprechen. Die Teilnehmer können über eine gebührenfreie Rufnummer für Nordamerika oder eine internationale Gebührennummer teilnehmen. Ein Audio-Webcast wird ebenfalls verfügbar sein, mit einer Aufzeichnung, die auf der Website des Unternehmens für diejenigen zugänglich ist, die nicht an der Live-Veranstaltung teilnehmen können.
- None.
- None.
MediPharm Labs executive management team will also host a conference call and audio webcast on Wednesday, August 14, 2024, at 8:30 a.m. (Eastern time) to discuss the Company's financial results.
Audio Conference Call Dial in Details:
North America Toll-Free: (888) 330-2454
International Toll: +1(240) 789-2714
Conference ID: 4921762
Participants are asked to dial in approximately 15 minutes before the start of the call.
Audio Webcast:
An audio webcast will be available by visiting the following link here.
For those who are unable to participate on the live conference call or webcast, a replay will be available at https://www.medipharmlabs.com/investors approximately one day after completion of the call.
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.
In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in
In 2023, MediPharm acquired VIVO Cannabis Inc. which expanded MediPharm's reach to medical patients in
The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm's filings, available on the SEDAR+ website at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
View original content to download multimedia:https://www.prnewswire.com/news-releases/r-e-p-e-a-t----medipharm-labs-sets-date-to-report-second-quarter-2024-financial-results-302218266.html
SOURCE MediPharm Labs Corp.
FAQ
When will MediPharm Labs (MEDIF) release its Q2 2024 financial results?
How can investors access MediPharm Labs' (MEDIF) Q2 2024 earnings call?
What is the conference ID for MediPharm Labs' (MEDIF) Q2 2024 earnings call?
Will there be a replay available for MediPharm Labs' (MEDIF) Q2 2024 earnings call?
